Aug 2 (Reuters) – UK drugmaker has been exploring a deal to mix with U.S. rival , the Monetary Instances reported on Sunday, citing folks aware of the matter.
The deal may create one of many world’s largest pharmaceutical teams with a mixed worth of almost $400 billion.
The businesses have held talks on a possible tie-up in current months, the report mentioned, including {that a} deal may materialise quickly, however is also delayed or disintegrate.
Reuters couldn’t instantly confirm the report. AstraZeneca declined to remark, whereas Bristol Myers didn’t instantly reply to a Reuters request for remark outdoors common enterprise hours.
Final yr, AstraZeneca unveiled plans for a direct U.S. itemizing, aiming to capitalise on stronger valuations within the U.S. market whereas remaining listed in London.
The corporate’s share worth has greater than quadrupled throughout Pascal Soriot’s 14-year tenure as CEO, hovering above the broader FTSE 100 index and fundamental British rival GSK.
Second-quarter outcomes final week confirmed robust demand for most cancers and uncommon illness medication continues to drive progress. Most cancers therapies accounted for about $25 billion in 2025 gross sales, almost half of the full, adopted by cardiovascular, renal and metabolism therapies price about $12 billion.
The report of the potential deal comes a couple of dozen years after AstraZeneca fended off a takeover try by bigger U.S. rival Pfizer.
